Wohl & Fruchter LLP Has Filed a Class Action Lawsuit on Behalf of Former Shareholders of Myovant Sciences, Ltd. in the U.S. District Court for the Southern District of New York
September 14, 2023 09:15 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on September 13, 2023, it filed a securities class action lawsuit in the United States District Court for the...
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
January 26, 2023 16:05 ET
|
Myovant Sciences, Inc.
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
November 16, 2022 16:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
November 16, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28,...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
October 26, 2022 08:30 ET
|
Myovant Sciences, Inc.
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have...
Myovant Sciences Cancels Second Quarter Earnings Conference Call
October 24, 2022 16:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
October 18, 2022 16:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
CORRECTION -- Myovant Sciences, Inc.
October 14, 2022 10:02 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
October 14, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for...
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
October 02, 2022 19:36 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”)...